How an AstraZeneca exec is leading the charge in the next immuno-oncology era

The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

By Michael Gibney • Aug. 17, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.

By Kelly Bilodeau • Aug. 14, 2023

What pharma companies are getting wrong about drug repositioning

Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.

By Alexandra Pecci • Aug. 9, 2023

Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

By Taren Grom and Meagan Parrish • Aug. 9, 2023

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

By Michael Gibney • Aug. 8, 2023

Pharma’s rocky love affair with oxytocin

Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.

By Kelly Bilodeau • Aug. 7, 2023

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023

As Barbie breaks the box office, women’s health investment explodes

Much like the year she first graced store shelves, Barbie has taken over the world. But now, the women's health landscape looks a whole lot different.

By Karissa Waddick • Aug. 2, 2023

A pharma banking on the success of past blockbusters

180 Life Sciences is on a mission to see if the anti-TNF technology that produced a blockbuster could work for a range of other conditions.

By Kelly Bilodeau • July 31, 2023

For Merck, understanding maternal mortality is the first step toward equity

Merck has invested for more than a decade in reducing maternal death rates in the U.S. and globally. Now for the next chapter.

By Michael Gibney • July 25, 2023

In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

By Alexandra Pecci • July 25, 2023

With the neuro tide rising, could a breakthrough for Parkinson’s be next?

Amid a wave of neuro R&D, scientists are taking an Alzheimer’s-like approach to developing the first disease-modifying treatments for Parkinson’s.

By Kelly Bilodeau • July 24, 2023

A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

By Taren Grom and Meagan Parrish • July 20, 2023

Google for genes? This AI company aims to curate the entire human genome.

Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge. 

By Michael Gibney • July 20, 2023

AI’s great expectations

With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development. 

By Karissa Waddick • July 19, 2023

What the 2014 Ebola outbreak taught this biotech CEO about persuasion

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

By Alexandra Pecci • July 18, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

Novo’s workhorse Ozempic could shine in new areas

Besides its popularity as a weight loss drug, Ozempic and treatments like it are being investigated for Alzheimer’s, liver disease and other surprising indications.

By Michael Gibney • July 13, 2023

FDA’s upcoming psychedelic review looms large for a budding industry

A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

By Karissa Waddick • July 12, 2023

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

By Alexandra Pecci • July 11, 2023

Cancer R&D is shifting — here’s what’s changing most

A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on new drug targets.

By Kelly Bilodeau • July 10, 2023

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Women’s healthcare investments are hot. So where are the new menopause drugs?

NK3 receptor antagonists offer a new option, but experts say more are needed.

By Kelly Bilodeau • July 5, 2023